Stop codon FGFR3 mutations in thanatophoric dwarfism type 1

[1]  P. Frosst,et al.  Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. , 1995, American journal of human genetics.

[2]  D. Rimoin,et al.  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.

[3]  W. Reardon,et al.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome , 1995, Nature Genetics.

[4]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[5]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[6]  R. Matthews,et al.  Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification , 1994, Nature Genetics.

[7]  H. Blom,et al.  Treatment of mild hyperhomocysteinemia in vascular disease patients. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[8]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[9]  W. Willett,et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.

[10]  J. Partanen,et al.  FGFR‐4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. , 1991, The EMBO journal.

[11]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[12]  M. Norusis,et al.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. , 1991, American journal of human genetics.

[13]  J. Kraut,et al.  Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. , 1990, Biochemistry.

[14]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[15]  S. S. Kang,et al.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. , 1988, American journal of human genetics.

[16]  G. Boers,et al.  Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. , 1985, The New England journal of medicine.

[17]  D. Eisenberg,et al.  Analysis of membrane and surface protein sequences with the hydrophobic moment plot. , 1984, Journal of molecular biology.

[18]  R. Matthews,et al.  Purification and properties of methylenetetrahydrofolate reductase from pig liver. , 1982, The Journal of biological chemistry.

[19]  D. Rosenblatt,et al.  Methylenetetrahydrofolate Reductase in Cultured Human Cells. II. Genetic and Biochemical Studies of Methylenetetrahydrofolate Reductase Deficiency , 1977, Pediatric Research.

[20]  J. Clegg,et al.  Haemoglobin Constant Spring—A Chain Termination Mutant ? , 1971, Nature.

[21]  A. George.  The metabolic basis of inherited disease , 1961 .

[22]  P. Wong,et al.  Methylenetetrahydrofolate Reductase in Coronary Artery Disease , 2005 .

[23]  H. Blom,et al.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. , 1995, American journal of human genetics.

[24]  R. Matthews,et al.  Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. , 1994, Nature genetics.

[25]  R M Horton,et al.  Gene splicing by overlap extension. , 1993, Methods in enzymology.

[26]  M. Golabi,et al.  Thanatophoric dysplasia and cloverleaf skull. , 1987, American journal of medical genetics. Supplement.